Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04799054 · ClinicalTrials.gov registry record · Phase 1
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Ascendis Pharma Oncology Division A/S.
- Terminated
- Registry status
- Phase 1
- Development phase
- 188
- Enrollment target
NCT04799054 is a Phase 1 study that was terminated before completion, run by Ascendis Pharma Oncology Division A/S. The registered enrollment target is 188 participants.
The verdict
NCT04799054, a Phase 1 study, was terminated before completion, sponsored by Ascendis Pharma Oncology Division A/S.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 188 participants
- Enrollment target
Study Summary
TransCon TLR7/8 Agonist is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This Phase 1/2 study will evaluate TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab in dose escalation and dose expansion. Participants will receive intratumoral (IT) injection of TransCon TLR7/8 Agonist every cycle. The primary objectives are to evaluate safety and tolerability, and define the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab.
Interventions
- DRUG Pembrolizumab
- DRUG TransCon TLR7/8 Agonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2021-03-18 |
| Est. Completion | 2025-12-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04799054
The ClinicalTrials.gov registry entry for NCT04799054 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascendis Pharma Oncology Division A/S, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04799054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04799054 about?
NCT04799054 is a clinical study titled "A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors". TransCon TLR7/8 Agonist is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This Phase 1/2 study will evaluate TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab in dose escalation and dose expansion. Participants will rec...
What is the current status of trial NCT04799054?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 188 participants. The study started on 2021-03-18. Estimated completion is 2025-12-02.
What interventions are being tested in trial NCT04799054?
The interventions under investigation include: Pembrolizumab (DRUG), TransCon TLR7/8 Agonist (DRUG).
Who is sponsoring clinical trial NCT04799054?
This trial is sponsored by Ascendis Pharma Oncology Division A/S, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.